ClinicalTrials.gg
CompletedNCT00309322Updated Nov 17, 2006

Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures

A Phase 2 interventional study of Phentolamine Mesylate (NV-101) in Anesthesia, Dental, sponsored by Novalar Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2006-11-17.

Sponsored by Novalar Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Hypesthesia with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Hypesthesia · United States.

Enrollment
3rd of 18
150 · median 72
Started
2006
with 2 others
Phase 2
5 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
4 of 20
Novalar Pharmaceuticals, Inc.

Among the 20 studies in Hypesthesia with a site in United States, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 2nd registered.

Hypesthesia

47 studies on the registry are indexed under Hypesthesia; 12 are open to participants now.

Browse Hypesthesia studies →

Open to participants now

2 of the 20 studies in Hypesthesia with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Hypesthesia studies recruiting now, 7 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 4 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hypesthesia with a site in United States, or all of them as a file.
02

Study summary

This Phase 2 clinical study is designed as a multicenter, randomized, blinded, controlled study to evaluate the safety and efficacy of NV-101 in approximately 150 children 4 to 11 years of age. NV-101 or sham injection is administered at the completion of a dental procedure requiring local anesthesia with 2% lidocaine with 1:100,000 epinephrine. The dental procedure(s) shall be performed in a single quadrant of the mouth and include cavity preparation, restoration/filling, teeth cleaning (non-surgical scaling and/or root planing), or crowns.

03

Conditions studied

  • Anesthesia, Dental

Browse trials for

Keywords

  • Soft Tissue Anesthesia (Numbness)
04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 4 to 11 years of age
  • Sufficiently healthy, as determined by the Investigator, to receive routine dental care
  • Requires a restorative procedure such as cavity preparation, or such as teeth cleaning (non-surgical scaling and/or root planing) in a single quadrant of the mouth
  • Requires local anesthesia with 2% lidocaine with 1:100,000 epinephrine administered by submucosal injection
  • Dental procedure(s) completed with 60 minutes of injection of local anesthetic
  • Can be trained to complete the Wong Baker Pain Rating Scale
  • For subjects 6 to 11 years of age who are trainable in standardized palpation procedure:

    • have normal lip sensation at baseline prior to administration of local anesthetic
    • have numbness of the relevant lip quadrant at completion of the dental procedure
  • Negative urine pregnancy test at screening in female subjects who are past menarche
  • Subjects give written or verbal assent, as applicable, and parents(s) or legal guardian(s) give written

Exclusion criteria

Exclusion Criteria:

  • Weight less than 15 kg
  • History or presence of any condition that contraindicates routine dental care or use of local anesthetic
  • Requires more than half cartridge of local anesthetic if weight is greater than or equal to 15 kg and less than 30 kg and more than one cartridge of local anesthetic if weight is greater than or equal to 30 kg, excluding supplemental injections
  • Allergy or intolerance to lidocaine, epinephrine, sulfites, phentolamine, or topical benzocaine
  • Has used any drug and/or participated in any clinical study within 30 days of study drug administration
  • Has participated in this study or any previous study of phentolamine mesylate for reversal of local soft tissue anesthesia (STA)
  • Use of opioid-like analgesics within 24 hours prior to administration of local anesthetic
  • Requires the use of local anesthetic other than lidocaine/epinephrine to perform the scheduled dental procedure
  • Requires the use of nitrous oxide or sedatives to perform the scheduled dental procedure
  • Any condition which, in the opinion of the Investigator, increases the risk to the subject of participating in the study or decreases the likelihood of compliance with the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single
Enrollment
150 participants
06

What researchers measure

Primary outcomes

  1. (All subjects) to evaluate the safety and tolerability of NV-101 as measured by: incidence, severity of adverse events

  2. incidence, severity and duration of intraoral pain as measured by Wong Baker Pain Rating Scale

  3. clinically significant changes in vital signs

  4. clinically significant changes in oral cavity assessments

  5. analgesics required for intraoral pain

Secondary outcomes

  1. (For subjects 6 to 11 years of age who are trainable in standardized palpation procedure): to determine if NV-101 accelerates the time to normal tongue sensation as measured by standardized palpation procedure

  2. for mandibular procedures, to determine if NV-101 accelerates the time to normal tongue sensation as measured by standardized palpation procedure

07

Study locations

1 site
  • The Forsyth Institute
    Boston, Massachusetts 02115, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2006
First posted
Mar 31, 2006
Start
Mar 2006
Completion
Aug 2006
Last update
Nov 17, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Nov 17, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00309322
Lead sponsor
Novalar Pharmaceuticals, Inc.
First posted
Mar 31, 2006
Start date
Mar 2006
Completion
Aug 2006
Last update
Nov 17, 2006

Study contacts

Mary Tavares, DDS
principal investigator · The Forsyth Institute
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phentolamine

Start the discussion